Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Tower power

Mon, 26th Oct 2020 11:03

* European shares down 0.6% but off opening lows

* Tech giant SAP dumps targets, shares tank

* Upbeat vaccine development lifts AstraZeneca
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

TOWER POWER (1001 GMT)

Equities in Europe have recovered from early lows and while
that may be due to underlying hopes the virus won't derail the
recovery, an outperformance of telco stocks is also
playing a part.

The sector is buoyed after Cellnex announced its
latest M&A move on Friday in a deal that highlights not only the
tower operator's successful acquisition strategy but also the
opportunity for traditional telecoms to monetise on their tower
assets.

Barclays estimates that 60% of towers in Western Europe are
still owned by operators and notes increasing commentary from
larger operators around exploring options for infrastructure.

"We continue to argue it makes sense to sell towers and
reallocate capital to other areas... Retaining minority stakes,
such as in the potential Play-Cellnex deal, allows operators to
participate in future upside that they are unlikely to realise
standalone," Barclays says.

On Friday Cellnex agreed to buy a 60% stake in the cellphone
tower unit of Play.

Telecoms were last leading sectoral gainers in
Europe, up 0.3%, with Cellnex leading the way, up 2.6%.

(Danilo Masoni)

*****

ANALYSTS’ MIXED VIEWS AFTER S&P MOVE ON ITALY (0909 GMT)

Probably many investors are wondering if S&P upgrading
Italy’s outlook is a "once and in a lifetime" move or a vote of
confidence on an enhanced European integration, which is getting
traction following ECB measures and the proposal of a EU
recovery fund.

Analysts’ views are mixed on the matter, but there’s no
doubt the rating agency action took investors by surprise as
10-year Btp yields are down 8 basis points this morning.

S&P said Italy's outlook balances the negative consequences
of the coronavirus pandemic on public finances against the
extraordinary policy response by the European Central Bank.

S&P move “confirms how creditworthiness really depends on
funding costs more than anything else,” a Citi research note
says.

But more headwinds might emerge “with poor absorption rate
of the EU funds and/or the crystallization of the Covid
government guarantees,” it adds.

Besides, some sort of debt consolidation might be necessary
in the future not to mention the political risk as “right-wing
parties championing a less-Europe ticket still gather nearly 40%
of voting intention.”

Unicredit analysts sound more optimistic.

The next ratings action for Italy will be from Moody’s on
November 6. “I’m pretty sure they won’t change anything on that
occasion, but S&P has now taken the lead on how the rating
agencies will – read: should - look at Europe,” its chief
economist Erik F. Nielsen says in a research note.

“The SURE bond issue sends two very clear messages: there is
a huge demand for a euro-denominated safe asset and there is
strong confidence in the new and enhanced European project,”
according to co-head of the research team Luca Cazzulani.

(Stefano Rebaudo)

*****

EUROPE OPENS IN THE DARK, BUT THERE'S SOME LIGHT (0841 GMT)

Losses are almost everywhere at the start of trading in
Europe with SAP leading the way, down 19% and set for
its worst day in 24 years, after the region's biggest tech
company dumped its targets, underscoring the big risks that the
second COVID-19 wave poses to the economic and corporate
recovery.

All country benchmarks are showing heavy declines in early
deals as worries over surging Covid cases dominate, and only
healthcare is managing to post a small gain with AstraZeneca
up marginally after an upbeat Financial Times report
about the vaccine developed by the UK drugmaker and the
University of Oxford.

The newspaper said their vaccine produced a robust immune
response in elderly people, the group at highest risk. Even
though that's not the kind of vaccine breakthrough investors are
looking for, it's still an encouraging development that can
keeps markets afloat despite the fresh lockdown risks.

Here's your snapshot:

(Danilo Masoni)

*****

ON OUR RADAR: SAP NEEDS A VACCINE TOO (0727 GMT)

Downbeat virus developments and no progress in U.S. stimulus
talks are surely a downer this morning but corporate newsflow
isn't helping either.

Shares in German software maker SAP are down 13%
in premarket trade after Europe's largest IT group by market
capitalisation cut its guidance for the year and abandoned its
forecast that profitability would expand steadily over the
medium term, saying coronavirus lockdowns would hit demand well
into 2021.

There's virus pain also for French car rental company
Europcar, which dropped its 2020 financial outlook as
it posted a slump in its Q3 results, hit by the impact of the
COVID-19 crisis.

Meantime, Lufthansa shares are down 2.3% in
premarket after the German airline said it would ground more
planes during winter.

In dealmaking news, U.S. buyout group Carlyle Group
is nearing an agreement to acquire Siemens mechanical
drive arm Flender, for about for about 2 billion euros,
Bloomberg News reported citing sources.

Frozen bread maker Aryzta said on Saturday it had
concluded discussions with Elliott Advisors without a binding
takeover offer and that it would now look at other options.

Eyes also on UK banks after the Times newspaper reported
that local regulators are considering plans to allow lenders to
start paying dividends again next year.

On the Covid treatment front however there's some good
looking newsflow. The FT reported that early results from tests
for the vaccine being developed by the University of Oxford and
AstraZeneca, show it produces a robust immune response
in elderly people.

(Danilo Masoni)

*****

MORNING CALL: COVID RISK-OFF (0637 GMT)

European shares were set to start the week in a clear
risk-off mood as Covid infections are surging rapidly across the
region, prompting new social restrictions that could hurt the
economic recovery.

Over the weekend Spain imposed local nighttime curfews and
banning travel between regions in some cases, while Italy
ordered bars and restaurants to close early and shut public
gyms, cinemas and swimming pools.

France registered a record 52,010 new confirmed coronavirus
infections over the past 24 hours.

Meantime in the United States, which saw its highest ever
number of new COVID-19 cases in the past two days,
there was no clear progress on a stimulus package.

Euro STOXX 50 futures were last down 1%, DAX futures down
1.3% and FTSE futures down 0.6%.

(Danilo Masoni)

*****

More News
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.